RCT | Sparsentan reduces proteinuria in patients with IgA nephropathy

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

PROTECT (Interim results): Sparsentan reduces proteinuria in patients with IgA Nephropathy (IgAN)#ISNWCN 🇹🇭 #Nephpearls#VisualAbstract by @dakidneydochttps://t.co/ViW9YncwI6 pic.twitter.com/zEGRSY8N3x

— Edgar V. Lerma 🇵🇭 (@edgarvlermamd) April 1, 2023